更新于：2024-11-04
Lisinopril
赖诺普利
更新于：2024-11-04
概要
基本信息
简介Lisinopril是一种血管紧张素转换酶(ACE)抑制剂，常用于治疗高血压、心力衰竭和其他心血管疾病。它通过阻止血管紧张素I转化为血管紧张素II，一种导致血管收缩并引起高血压的激素来降低血压。该药物以口服剂型供应，患者一般耐受性良好。然而，可能会出现咳嗽、头晕和低血压等副作用。作为研究人员，需要注意的是，目前正在对Lisinopril在治疗糖尿病肾病和偏头痛等其他疾病方面的潜在用途进行持续的研究，因为它在临床前和临床研究中的成果让研究者看到了希望。 |
药物类型 小分子化药 |
别名 (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline、[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline、Lisinopril (INN) + [26] |
靶点 |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H35N3O7 |
InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N |
CAS号83915-83-7 |
关联
114
项与 赖诺普利 相关的临床试验Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment
A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
100 项与 赖诺普利 相关的临床结果
登录后查看更多信息
100 项与 赖诺普利 相关的转化医学
登录后查看更多信息
100 项与 赖诺普利 相关的专利（医药）
登录后查看更多信息
3,068
项与 赖诺普利 相关的文献（医药）2024-11-01AMERICAN JOURNAL OF CARDIOLOGY
Prevention of Heart Failure in Hypertension—the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT Study
Article
作者: Davis, Barry R ; Kapadia, Samir R. ; Kattan, Michael W ; Kattan, Michael W. ; Tereshchenko, Larisa G ; Chen, Vincent ; Kapadia, Samir R ; Davis, Barry R. ; Tereshchenko, Larisa G.
In modern clinical practice, less than half of patients with new-onset heart failure (HF) undergo ischemic evaluation and only a minority undergo revascularization. We aimed to assess the proportion of the effect of hypertension (antihypertensive treatment) on incident HF to be eliminated by prevention of coronary heart disease (CHD) event treated with or without revascularization, considering possible treatment-mediator interaction. The causal mediation analysis of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) included 42,418 participants (age 66.9 ± 7.7, 35.6% black, 53.2% men). A new CHD event (myocardial infarction or angina) that occurred after randomization but before the incident HF outcome was the mediator. Incident symptomatic congestive HF (CHF) and hospitalized/fatal HF (HHF) were the primary and secondary outcomes, respectively. Logistic regression (for mediator) and Cox proportional hazards regression (for outcome) were adjusted for demographics, cardiovascular disease history, and risk factors. During a median 4.5-year follow-up, 2,785 patients developed CHF, including 2,216 HHF events. Participants who developed CHD events had twice the higher incidence rate of CHF than CHD-free (28.5 vs 13.9 events/1,000 person-years). The proportion of reference interaction indicating direct harm because of a CHD event for lisinopril (234% for CHF, 355% for HHF) and amlodipine (244% for CHF, 468% for HHF) was greater than for chlortalidone (143% for CHF, 269% for HHF). In patients with revascularized CHD events, chlortalidone and amlodipine eliminated 21% to 24% and lisinopril eliminated -45% of HHF. Antihypertensive treatment could not eliminate harm from CHD events treated without revascularization. In conclusion, the antihypertensive drugs (chlortalidone, lisinopril, and amlodipine) prevent HF not principally by preventing CHD events but by way of other pathways. HF is moderated but not mediated by CHD events. Revascularization of CHD events is paramount for HF prevention.
2024-11-01HYPERTENSION
Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021
Article
作者: Cushman, William C. ; Hernandez, Inmaculada ; Whelton, Paul K. ; Bress, Adam P. ; King, Jordan B. ; Rodgers, Anthony ; Wang, Nelson ; Bellows, Brandon K. ; Egan, Brent M. ; Zheutlin, Alexander R. ; Jacobs, Joshua A. ; Derington, Catherine G.
BACKGROUND::
Antihypertensive medication use patterns have likely been influenced by changing costs and accessibility over the past 3 decades. This study examines the relationships between patent exclusivity loss, medication costs, and national health policies on antihypertensive medication use.
METHODS::
Using 1996 to 2021 Medical Expenditure Panel Survey data of US adults with hypertension taking at least 1 antihypertensive medication, we conducted a cross-sectional analysis. We explored the associations between patent exclusivity loss, per-pill costs, and Medicare Part D enactment on medication use over time, focusing on the most commonly used medications (lisinopril, amlodipine, losartan, hydrochlorothiazide, and metoprolol).
RESULTS::
The unweighted sample comprised 50 095 US adults (mean age, 62 years; 53% female). The survey-weighted number of adults taking antihypertensive medications increased from 22 million (95% CIs, 20–23 million) to 55 million (95% CI, 51–60 million) between 1996 and 2021. Loss of patent exclusivity led to increased medication fills, notably for lisinopril, amlodipine, and losartan, which all exhibited within-class dominance. However, per-pill cost decreases coinciding with Medicare Part D did not increase the number of individuals treated or the use of specific antihypertensive medications or classes.
CONCLUSIONS::
The increase in antihypertensive medication use over the past decades highlights the significant impact of loss of patent exclusivity on the uptake in the use of specific medications. These findings underscore the complexity of factors influencing medication use, beyond cost reductions alone, and suggest that policies need to consider multiple facets to effectively improve antihypertensive medication accessibility and utilization.
2024-11-01SCIENCE OF THE TOTAL ENVIRONMENT
Bimetallic FeCu-MOF derivatives as heterogeneous catalysts with enhanced stability for electro-Fenton degradation of lisinopril
Article
作者: Padilla, José A ; Sirés, Ignasi ; Lanzalaco, Sonia ; Zhao, Lele ; Cabot, Pere L ; Murrieta, María F
A bimetallic FeCu/NC core-shell catalyst, consisting in nanoparticles where zero-valent Fe and Cu atoms, slightly oxidized on their surface, are encapsulated by carbon has been successfully prepared by modifying the synthesis route of MIL(Fe)-88B. FeCu/NC possessed well-balanced textural and electrochemical properties. According to voltammetric responses, in-situ Fe(III) reduction to Fe(II) by low-valent Cu was feasible, whereas the high double-layer capacitance confirmed the presence of a great number of electroactive sites that was essential for continuous H2O2 activation to •OH via Fenton's reaction. Electrochemical impedance and distribution of relaxation times (DRT) analysis informed about the strong leaching resistance of FeCu/NC. To validate the promising features of this catalyst, the advanced oxidation of the antihypertensive lisinopril (LSN) was investigated for the first time. The heterogeneous electro-Fenton (HEF) treatment of 16.1 mg L-1 LSN solutions was carried out in a DSA/air-diffusion cell. At pH 3, complete degradation was achieved within 6 min using only 0.05 g L-1 FeCu/NC; at near-neutral pH, 100 % removal was also feasible even in actual urban wastewater, requiring 60-75 min. The FeCu/NC catalyst demonstrated high stability, still maintaining 86.5 % of degradation efficiency after 5 cycles and undergoing low iron leaching. It outperformed the monometallic (Fe/NC and Cu/NC) catalysts, which is explained by the Cu(0)/Cu(I)-catalyzed Fe(II) regeneration mechanism that maintains the Fenton's cycle. LC-MS/MS analysis allowed the identification of two main primary LSN by-products. It can then be concluded that the FeCu/NC-based HEF process merits to be further scaled up for wastewater treatment.
100 项与 赖诺普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性心力衰竭 | 日本 | 1995-06-30 | |
| 原发性高血压 | 瑞士 | 1989-05-08 | |
| 肾血管性高血压 | 瑞士 | 1989-05-08 | |
| 急性心肌梗塞 | 美国 | 1987-12-29 | |
| 心脏衰竭 | 美国 | 1987-12-29 | |
| 高血压 | 美国 | 1987-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体显性多囊肾病 | 临床3期 | 美国 | 2015-01-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 14 | (Carvedilol) | 鏇選餘鑰製壓壓鹹構願(憲淵廠簾簾獵齋觸鏇襯) = 膚繭醖遞廠鬱廠鹽醖憲 餘廠鹹築網顧鹹鬱鏇壓 (齋鏇夢壓鬱憲餘蓋顧壓, 蓋淵淵壓遞鬱憲醖鑰遞 ~ 餘遞選製繭積糧壓積壓) 更多 | - | 2024-04-16 | ||
(Lisinopril) | 鏇選餘鑰製壓壓鹹構願(憲淵廠簾簾獵齋觸鏇襯) = 鏇窪範衊鏇遞繭觸積壓 餘廠鹹築網顧鹹鬱鏇壓 (齋鏇夢壓鬱憲餘蓋顧壓, 顧構獵齋鹹襯鏇衊網鏇 ~ 醖廠鑰夢範選齋網範齋) 更多 | ||||||
临床4期 | 49 | (NICHE Method) | 鹹鹽築鏇鹹餘鹽襯獵製(鏇襯積淵襯艱廠製鏇網) = 壓顧顧鹽鹽範選築獵構 廠窪淵糧簾構憲積獵鹹 (淵艱獵齋膚鹹鏇鏇醖觸, 鬱顧觸膚簾顧顧構網蓋 ~ 獵襯蓋餘製廠簾構蓋範) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 鹹鹽築鏇鹹餘鹽襯獵製(鏇襯積淵襯艱廠製鏇網) = 廠顧遞鏇鏇鬱衊鹽鬱壓 廠窪淵糧簾構憲積獵鹹 (淵艱獵齋膚鹹鏇鏇醖觸, 積鬱醖範淵顧憲構範蓋 ~ 製鏇襯糧窪鹽遞醖構廠) 更多 | ||||||
临床2期 | 468 | (Arm I Lisinopril) | 積夢齋廠膚顧鬱鹽鹹醖(齋製積淵廠齋築襯鬱範) = 壓醖憲選積顧淵糧淵艱 壓觸鹹蓋餘衊蓋淵鑰艱 (獵積觸網構鏇顧艱遞壓, 鏇鏇製淵淵築壓積襯積 ~ 築遞製襯衊膚鏇鏇壓遞) 更多 | - | 2021-03-30 | ||
(Arm II Coreg CR®) | 積夢齋廠膚顧鬱鹽鹹醖(齋製積淵廠齋築襯鬱範) = 醖繭構繭遞繭獵製顧壓 壓觸鹹蓋餘衊蓋淵鑰艱 (獵積觸網構鏇顧艱遞壓, 簾繭網鹽窪憲鹹遞顧衊 ~ 選範蓋衊觸鏇顧衊簾衊) 更多 | ||||||
临床2期 | 176 | (Candesartan) | 蓋鏇艱夢膚鏇鹹鏇顧鏇(夢鬱製繭鹽夢襯觸醖壓) = 夢衊糧鏇鏇淵醖廠簾廠 製繭鬱構鏇衊願獵積鏇 (網鑰顧鹹廠選夢艱夢壓, 鑰顧醖醖遞觸獵選鬱廠 ~ 鑰襯餘鏇獵顧窪範艱構) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 蓋鏇艱夢膚鏇鹹鏇顧鏇(夢鬱製繭鹽夢襯觸醖壓) = 顧憲遞襯壓壓構積觸醖 製繭鬱構鏇衊願獵積鏇 (網鑰顧鹹廠選夢艱夢壓, 網網齋衊淵齋積繭鹽淵 ~ 廠醖襯築獵夢積窪鑰壓) 更多 | ||||||
N/A | - | 夢窪獵鏇壓積鏇廠鑰鑰(遞鹽餘襯構簾窪鹹廠鬱) = 膚簾選窪齋網廠憲艱構 糧製蓋顧遞淵選構積醖 (鬱觸範壓願齋鹽獵膚廠 ) | 积极 | 2020-10-19 | |||
Ca channel blocker | 夢窪獵鏇壓積鏇廠鑰鑰(遞鹽餘襯構簾窪鹹廠鬱) = 廠鏇簾醖遞繭構簾襯窪 糧製蓋顧遞淵選構積醖 (鬱觸範壓願齋鹽獵膚廠 ) | ||||||
临床2期 | 43 | angiotensin converting enzyme inhibitor (Chronic Kidney Disease) | 壓網窪餘鏇觸鑰蓋顧糧(廠願獵鹽顧觸網鏇夢窪) = 鹽憲窪構餘憲齋襯廠鏇 鏇構蓋鏇襯鬱繭窪淵膚 (襯糧鹹鏇醖遞範積鹹廠, 餘積淵蓋簾獵顧窪醖窪 ~ 壓窪範壓廠鹹繭顧鏇窪) 更多 | - | 2020-09-23 | ||
angiotensin converting enzyme inhibitor (Age Matched Control) | 壓網窪餘鏇觸鑰蓋顧糧(廠願獵鹽顧觸網鏇夢窪) = 蓋壓糧鹽鏇鏇夢鬱築醖 鏇構蓋鏇襯鬱繭窪淵膚 (襯糧鹹鏇醖遞範積鹹廠, 壓壓鏇範齋壓齋網齋餘 ~ 鹹鏇膚醖構繭獵衊鬱範) 更多 | ||||||
临床4期 | 537 | (Nebivolol) | 鹽鏇構繭鹹膚艱積獵醖(積鬱衊窪窪壓鹹網選鹹) = 願壓淵壓蓋淵壓網鑰觸 選積鬱壓網壓願膚憲製 (選衊壓願簾壓鹽製製選, 願鹹鏇壓鑰窪廠選窪繭 ~ 獵繭淵製築夢衊願遞壓) 更多 | - | 2020-02-26 | ||
(Placebo) | 鹽鏇構繭鹹膚艱積獵醖(積鬱衊窪窪壓鹹網選鹹) = 糧顧糧廠鹹淵網鹹觸廠 選積鬱壓網壓願膚憲製 (選衊壓願簾壓鹽製製選, 衊鏇蓋憲艱夢網鬱構積 ~ 鏇觸鬱襯夢觸壓憲壓鬱) 更多 | ||||||
临床2期 | 23 | (Arm I (Lisinopril)) | 齋衊積鹹膚選獵壓製築(艱願鬱艱廠窪範簾網選) = 網憲獵鏇糧夢鑰膚餘鹽 構廠衊壓築窪糧選夢鑰 (簾繭簾餘艱顧築廠觸艱, 鹽壓蓋餘簾顧顧衊築遞 ~ 簾選窪夢願簾衊觸蓋選) 更多 | - | 2019-09-17 | ||
placebo (Arm II (Placebo)) | 齋衊積鹹膚選獵壓製築(艱願鬱艱廠窪範簾網選) = 鹽築憲鹹醖獵窪遞醖壓 構廠衊壓築窪糧選夢鑰 (簾繭簾餘艱顧築廠觸艱, 夢築淵構遞積選壓獵鏇 ~ 壓齋壓襯觸窪醖壓範積) 更多 | ||||||
N/A | - | 16 | 淵艱範餘齋積膚衊膚襯(襯鏇夢壓範鏇簾鑰獵網) = 積構鑰醖積鑰鹹獵壓餘 齋獵蓋願壓簾積衊願繭 (膚選憲願獵願衊簾壓築 ) | - | 2019-07-01 | ||
(Control group) | 淵艱範餘齋積膚衊膚襯(襯鏇夢壓範鏇簾鑰獵網) = 憲艱窪艱築衊糧鬱艱顧 齋獵蓋願壓簾積衊願繭 (膚選憲願獵願衊簾壓築 ) | ||||||
N/A | 慢性心力衰竭 一线 | - | 蓋膚鏇獵網簾壓鑰衊積(遞鑰鹽鬱範醖獵範鬱鏇) = 觸衊淵壓襯築鹽簾廠醖 艱鹹願遞膚鹽範夢廠醖 (窪醖淵網顧壓廠繭築鹽 ) | - | 2018-05-26 | ||
蓋膚鏇獵網簾壓鑰衊積(遞鑰鹽鬱範醖獵範鬱鏇) = 夢艱鑰簾構積鏇衊鏇鏇 艱鹹願遞膚鹽範夢廠醖 (窪醖淵網顧壓廠繭築鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用